Bioidentical Hormone Replacement Therapy Considerations

Introduction to Bioidentical Hormones

Bioidentical hormone replacement therapy is not recommended for the prevention of chronic diseases in postmenopausal women due to lack of FDA approval and insufficient evidence regarding safety and efficacy, as stated by the Annals of Internal Medicine 1, 2
The FDA defines "bioidentical hormone replacement therapy" as a marketing term rather than a formally defined drug classification 2

The FDA has not approved any type or class of bioidentical hormone therapy for the prevention of chronic diseases in postmenopausal women 2
No randomized trials have studied the potential benefits or harms of bioidentical hormones for the prevention of chronic conditions in postmenopausal women 2
The safety and effectiveness of these products have not been evaluated through the FDA's drug approval process 2

The Women's Health Initiative (WHI) study demonstrated that hormone therapy (estrogen plus progestin) was associated with increased risks of breast cancer 3, coronary heart disease 4, stroke 4, venous thromboembolism 4, and gallbladder disease 5
These risks must be considered when discussing any form of hormone therapy, including bioidentical hormones 4, 6

The American College of Obstetricians and Gynecologists and other societies recommend against using hormone therapy for primary or secondary prevention of cardiovascular disease 7
Patients should be informed that claims about the superior safety of bioidentical hormones are not supported by scientific evidence 2
Hormone therapy of any kind is not recommended for the prevention of chronic conditions such as cardiovascular disease, osteoporosis, or dementia 2, 7
The North American Menopause Society, American Heart Association, and American Congress of Obstetricians and Gynecologists all recommend against using hormone therapy for primary or secondary prevention of cardiovascular disease 7
Prescribing hormone therapy for prevention of chronic conditions rather than for symptom management should be avoided 2, 8
Failing to discuss both the potential benefits and risks of any hormone therapy with patients should be avoided 6
When discussing hormone therapy options with patients, focus on FDA-approved formulations, evidence-based approaches, and individualized risk assessment based on medical history and symptom severity 7

The National Comprehensive Cancer Network recommends against the use of custom-compounded bioidentical hormones due to lack of safety and efficacy data, lack of standardization, and unsubstantiated marketing claims. 9
The American College of Physicians states that many FDA-approved conventional hormone therapies actually contain bioidentical hormones, which are chemically identical to human hormones. 10

The National Comprehensive Cancer Network notes that all estrogen-based hormone therapies, regardless of source, carry similar risks demonstrated in the Women's Health Initiative (WHI) trial, including increased risk of coronary heart disease events, stroke, and venous thromboembolism. 10
The American College of Physicians reports that estrogen-based hormone therapies also carry an increased risk of breast cancer with estrogen plus progestin therapy, with a relative risk of 1.24. 10, 11
The National Comprehensive Cancer Network states that hormone therapy of any type is contraindicated in women with a history of hormone-dependent cancers, venous thromboembolism, active or recent stroke or coronary heart disease, and active liver disease. 9, 12

The National Comprehensive Cancer Network recommends using FDA-approved formulations of bioidentical hormones at the lowest effective dose for the shortest duration to treat moderate to severe menopausal symptoms. 9
The National Comprehensive Cancer Network suggests that transdermal estradiol formulations may be preferred over oral due to lower rates of venous thromboembolism and stroke. 9
The National Comprehensive Cancer Network recommends using micronized progesterone over medroxyprogesterone acetate due to lower rates of venous thromboembolism and breast cancer risk. 9

The FDA states that "bioidentical hormone replacement therapy" is a marketing term rather than a formally defined drug classification, emphasizing the distinction between marketing and medical classification 13
No randomized controlled trials have studied the potential benefits or harms of custom-compounded bioidentical hormones for the prevention of chronic conditions or symptom management in postmenopausal women, representing a fundamental gap in evidence 13

All estrogen-based hormone therapies, regardless of source or whether they are labeled "bioidentical," carry similar risks, including increased coronary heart disease events (7 additional per 10,000 women-years), increased stroke (8 additional per 10,000 women-years), increased venous thromboembolism (8 additional per 10,000 women-years), and increased invasive breast cancer with estrogen-plus-progestin (8 additional per 10,000 women-years) 13
Custom-compounded preparations introduce risks beyond those of conventional hormone therapy, including lack of standardization, no FDA oversight, unproven formulations, and inappropriate dosing guidance 13

The U.S. Preventive Services Task Force, American Heart Association, American Congress of Obstetricians and Gynecologists, and National Comprehensive Cancer Network all recommend against the use of custom-compounded bioidentical hormones 13, 14
The National Comprehensive Cancer Network explicitly notes there is no data supporting claims that custom-compounded bioidentical hormones are safer and more effective than standard hormone therapies 14

Hormone therapy is contraindicated in patients with a history of hormone-dependent cancers, history of venous thromboembolism, active or recent stroke or coronary heart disease, and active liver disease 14
The American College of Obstetricians and Gynecologists recommends using the lowest effective dose for the shortest duration necessary to control symptoms, and prefers transdermal estradiol over oral formulations due to lower thrombotic risk, and micronized progesterone over medroxyprogesterone acetate for endometrial protection 13